Navigation Links


Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Researchat Helix BioPharma Corp., a developer of novel cancer therapeutics,will be presenting a scientific poster at the Fourth InternationalConference on Tumor Microenvironment, which runs from March 6th to10th in Florence, Italy. The conference, hosted by the...

Replidyne Phase II Pediatric Trial Meets Primary Objective

LOUISVILLE, Colo., March 06, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. announced today that it has completed its Phase IIclinical trial using faropenem medoxomil (faropenem) in pediatricpatients with acute otitis media (AOM), a common infection of themiddle ear. Initial analyses of the study results show that it metits primary objective to show that faropenem was effective ineradicatin...

DVT Awareness Survey Findings: Heart and Respiratory Patients

WASHINGTON, March 06, 2007 /PRNewswire/ -- Up to two millionAmericans are affected each year by DVT, with up to 600,000hospitalized. Its primary complication, pulmonary embolism (PE),claims up to 300,000 lives annually -- more than breast cancer andAIDS combined. People who suffer from cardiovascular disease may beat increased risk for DVT, because these factors also heighten thelikelihood...

Pozen Announces Positive Outcome for PA 325

Chapel Hill, N.C., March 6, 2007-Pozen Inc. (NASDAQ: POZN),today announced top-line results of its "Safer Aspirin" PA 325proof-of-concept study conducted during the fourth quarter of 2006.PA 325 is a patented formulation of 325mg of aspirin surrounded bya 20mg coating of an immediate release formulation of a proton pumpinhibitor. The PA 325, 28 day study, involved two groups of 40 subject...

Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings

CAMBRIDGE, Mass., March 06, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced that data from three completedPhase III multi- center clinical studies of ferumoxytol as anintravenous iron replacement therapeutic will be presented duringthe National Kidney Foundation (NKF) 2007 Spring Clinical Meetingstaking place April 10th through 14th in Orlando, Florida. Twoposters containi...

POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc.(NASDAQ: POZN), today announced top-line results of its "SaferAspirin" PA 325 proof-of-concept study conducted during the fourthquarter of 2006. PA 325 is a patented formulation of 325mg ofaspirin surrounded by a 20mg coating of an immediate releaseformulation of a proton pump inhibitor. The PA 325, 28 day study, involved two group...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

- 78 Percent of Patients Showed Complete Response or Reduction ofLesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - NventaBiopharmaceuticals Corporation today announced the presentation ofpositive results from a clinical trial examining the safety andefficacy of pilot process HspE7, an investigational therapeuticvaccine for human papillomavirus (...

AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy

VIENNA, Austria and CHAPEL HILL, N.C., US, March 06, 2007/PRNewswire/ -- AOP Orphan Pharmaceuticals AG ("AOP Orphan") andLantibio, Inc. ("Lantibio") today announced positive final resultsfrom their placebo controlled, double-blinded Phase II clinicalstudy of Moli1901, an experimental compound to treat cysticfibrosis ("CF"). Moli1901 is being developed by AOP Orphan inEurope under a licensi...

Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 5, 2007 - Advanced CellTechnology, Inc.'s (OTCBB: ACTC) ability to rescue vision in blindrats was noted in Scientific American's March 2007 issue as thelead story of its News Scan section. The full text of the article,which notes Advanced Cell's ability to "coax embryonic stem cellsto turn into transplantable retinal pigment epithelial (RPE)tissue," is...

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters atthe Annual Meeting of the American Academy of Allergy, Asthma, andImmunology from February 23 - 27, 2007 in San Diego, CA. Theposters discussed findings from a survey of 202 otolaryngologists(ENTs) and allergists in the U.S., U.K., France, and Germany on theburden of chroni...
[next]
(Date:11/8/2018)... , ... November 08, 2018 , ... ... hair removal and leg vascular skin conditions with Cuter Excel HR™ Laser, a ... Surgery Center and MedSpa has invested in the state-of-the-art Cutera Excel HR™ Laser ...
(Date:11/8/2018)... ... November 08, 2018 , ... The Salt Lake Tribune named Tranont a ... list is compiled solely on employee feedback gathered through a third-party survey. The anonymous ... name a few. , “We strive to treat everyone like family here at Tranont,” ...
(Date:11/7/2018)... ... November 07, 2018 , ... AccentCare, managed by Veteran leadership, is proud ... , “We thank Veterans everywhere for ensuring our freedom and are humbled every day ... said AccentCare CEO Steve Rodgers, who was a Special Forces Medic in the U.S. ...
(Date:11/7/2018)... ... November 07, 2018 , ... According ... benefits of human growth hormone (HGH) replacement therapy, for men and women suffering ... that for various reasons, many patients have reservations about taking HGH, and for ...
(Date:11/7/2018)... N.C. (PRWEB) , ... November 07, 2018 , ... ... leader ProEdTech, will host the live, 6-hour Virtual Boot Camp titled “ Pain ... Amy Turner on November 29-30, 2018. , Attendees will learn about the most ...
Breaking Medicine News(10 mins):
Standard Erlanger hip stem....
Porous foundation 480 series....
Cemented foundation 450 series....
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
Medicine Products:
(Date:11/9/2018)... ... ... The London office of global law firm Greenberg Traurig, LLP ... rights to Nexium for an upfront payment of USD700 million with further sales-related and ... that decreases the amount of acid produced in the stomach. The law firm also ...
(Date:11/8/2018)... BEACH, Calif. (PRWEB) , ... ... ... Inc. has expanded its treatment center to include dedicated residential facilities specifically ... recovery risks faced by individuals after the band, bypass or sleeve procedures. ...
(Date:11/8/2018)... ... November 08, 2018 , ... ... in Blue Ash, OH, one of Cincinnati’s most prosperous business and innovation corridors. ... labs and expanded capabilities. , “These changes mark a huge milestone for ...
Breaking Medicine Technology: